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m8012 Is Theres Differential Benefit of ReoPro During
PTCA for Patients with Ceftein Lesion wpes?
S. Ellis, A.M. Lincoff, J.E. Tcheng, D.P. Mil16r,J.E. Booth, R.M. Califf,
E. Topol for the EPILOG Study Participants. Cleveland Clinic foundation,
Cleveland, OH, USA
Targeting patients (pts) especially likely to benefit from ReoPro (R) (ab-
ciximab) would increase its cost-effectiveness. Data from the EPIC study
suggested that pts with type A or B1 (simple) lesions might have more acute
benefit from R than pts with B2 orC (complex) lesions. This assessment was
confounded by the linkage between unstable angina and type A or BI le-
sions because of the inclusion criteria of the study. We assessed the relation
between ReoPro use, lesion type and 30 day death, Ml or urgent PTCA or
CABG (comp) in EPILOG, which did not require unstable angina or Ml with
type A or B1 IeaionS.
Treatment % COmp
A B1 B2 c
n = 278 n = 507 n = 147S n = 489
Placatm + SD hepsrin (n = 939) 5,7 5.2 14.5 14.2
R + LD heparln (n = 935) 2.1 4.3 4.5 8.3
R + SD hepsrin (n = 918) 6.4 2.4 5.3 5.4
p value NS NS <0.001 0.12
SD= stendarddoas LD = low dose
Thus whereas all pts shared in the overall 57% reduction in 30 day
death/Ml from ReoPro in EPILOG, those with complex lesions treated ap-
peared to benefit most. Acomplete economic analysis will require long-term
follow-up data which is not yet available.
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[801-3] Analysis Of+fosPita,Costssnd ~ut~ome*in
RESTORE
RESTORE Economic Study Group. Emory Univj Atlanta, GA, USA
The RESTORE trial (Randomized Efficacy of Study of Tirofibanfor Outcomes
and Restenosis) was a randomized, double-blind, placebo controlled trial of
tirofiban in 2,139 patients undergoing PTCA within 72 hours of presentation
with unstable angina pectoris or acute myocerdial infarction (Ml). Patients
were treated with tirofiban 10 wg/kg over 3 minutes followed by a 36 hour
infusion of 0.15 pglkg/min or placebo. At 2 days there was a 36% reduction
(8.7% vs 5.4%, p = 0.005) in the composite endpoint of death, non-fatal Ml,
coronary eurgefy due to PTCA failure or recurrent ischemia, repeat target
vessel angioplasfy for recurrent ischemia, or insertion of a stent due to actual
or threatened abrupt closure of the dilated artery. This was due largely to
a decrease in non-fatal Ml by 39% (4.4% vs 2.7%, p = 0.039) and repeat
PTCA by 66% (3.2~o vs 1.1%, p = 0.001). A cost substudy was carried out in
759 patients in 30 hospitals. Hospital charges were obtained from the UB92
formulation of the hospital bill and then the charges were converted to cost
using the cost-to-charge ratios from the individual hospitals. The average
hospital cost in the tirofiban group was $9699 ($279 SE) vs $10,279 ($~o
SE) in the placebo group (offset $380, 95% Cl –430 to 1190).These costs
reflect original hospital costs only and do not include professional or follow-up
costs. Multiple regression was used to determine the additional cost (AC) of
multivariate correlates including subsequent coronary sur9efY (AC $18347,
p < O.0001), additional PTCA (AC $6214, P < 0.0001), non-fatal Ml (AC
$4591, p < 0.0001), stent insertion (AC $5000, p = 0.0004), and a history of
heari failure (AC $5292, p c 0.0001), with an R-sq of 0.49. If length of stay
is added to the model (AC $829 per additional day, P < O.0001)the R-sq
rises to 0.65. The main drivera of AC (except heart failure) are treatment
modifiable. While there was only a trend to lower cost with treatment, it is
likely that an early dramatic reduction in events after high risk PTCA can be
achieved with anti-platelet therapy without raising costs.
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801-4 Prevention of abrupt vessel closure following PTCA
by Intracoronary dipyridemole. A prospectively
randomised trial in 1094 consecutive interventions
U.E. Heidland, M.P. Heintzen, W.J. Klimek, B. Schwarfzkopff, M. Kelm,
E.G. Vester, M. Leschke, B.E. Strauer. Heinrich-Heine-Univefaify
Dfiseeldofl Germany
Acute coronary artery Occlusionfollowing PTCAisapotentiaWl ife-threatening
complication. Dipyridamole (dip) induces dilatation of coronary arteries and
prevents platelet aggregation. The purpose of the study is to evaluate if
adjunctive Ibcal intracoronafy therapy with dip reduces the incidence of coro-
nary artery occlusion following PTCA. In 940 PTCA performances for stable
ischemia and in 154 emergency angioplasty procedures (instable angina
pectoris, myocardial infar~ion) patients were randomised to receive conven-
tional pretreatment consisting of heparin 15000 I.E. and aspirin 500 mg iv.
or additional intracoronary infusion of dip (0.5 mg/kg bodyweight). Dip. was
applied in 550 interventions (451 men, 90 women, age = 59.2 + 4.2; 73
emergency procedures); conventional pretreatment was performed in 544
patients (443 men, 92 women, age= 56.3 +5.8; 61 emergency procedures).
The incidence of coronary artery occlusion is depicted in the tabula (data
given as absolute values and as percentages).
Dipyridamole Conventional p-value
Total(n= 1094) 14 (2.5”/.) 33 (6.1°/0) n nn,4
Elective(n= 940)
“.. -
10 (2,1%) 20 (4,3%) 0.05
Emergency (n= 154) 4 (5.5%) 13 (16.00/.) 0.04
It is mncluded, that intrecoronary dipyridamole reduces the incidence of
abrupt vessel closure following PTCA for stable ischemia and acute coronary
insufficiency syndromes.
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~f p~ventionofReocc,”s,on AfierSuccessfu, Ba,,oon
PTCA of Totally Occluded Coronary Arteries: a
Prospective Randomized Pilot-Study Comparing
Ticlopidine-Aspirin Association with Aspirin slone
A. Cerisier, K. Isaaz, A. DaCosta,C. Venet, J.-P. De Pasquale, .M. Lamaud.
Division of Cardiology C.H.U de Saint-Etienne, Saint-Etienne, France
High reocclusion and restenosis rate is an important limitation for balloon
PTCA of totally occluded coronary arteries. Recent reports have validated
the use of stents to improve late angiographic outcome of balloon PTCA in
patients with ?3.0 mm coronary artery reference diameter but the useful-
ness of stenting <3.0 mm totally occluded coronary arteries remains to be
validated. In the present study, we evaluated the impact of Ticlopidine plus
Aspirin (T-A), a strong antiplatelet regimen, on the restenosis and reccclu-
sion rate after successful balloon PTCA of coronary artery total occlusion
(TIMI O)with reference diameter less than 3.0 mm. Nineteen symptomatic
patients who undenvent successful ballocmPTCA for totally occluded artery
(occlusion to PTCAtime: 20 + 13 days) were randomized to take 500 mg of
Ticlopidine plus 100 mg Aspirin (T-A, 10 pts) or to take 250 mg Aspirin alone
(A, 9 pts) during 6months. Quantitative coronary angiography was performed
immediately after PTCA (1)and at 6 months (Fu). There was no difference
between the 2 groups regarding age, sex ratio, risk factore, ejection fraction,
occlusion Imalization, occlusion to PTCA time.
Results:
Ref. diam. (mm) “/0atenosisI ‘h atenosia Fu TIMIO Fu
T-A (n= 10) 2,4 + 0.4 32* 5 54• 19 0/10
A (n = 9) 2.4 + 0.3 34& 11 52 * 31” 6r9*
Thus, Ticlopidine-Aspirin assckiation appears to be more effective than
Aspirin alone to improve late angiographic outcome after successful balloon
PTCA recanalization of totally occluded arteries. (*p c 0.05)
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[801-61 bWreasedThrombinActivitY,n patientsWith
Unstable Ischemic Syndromes Correlate With
Long-term Clinical Events After Angioplasty: Lack of
Efficacy of Locally Delivered Urokinase
J.M. Pyles, R.L. Wilensky. Indiana University hrdianapolis, /Nand
University of Pennsylvania, Philadelphia, PA, USA
lntracorona~ thrombus during PTCA leads to an increased flsk of coronary
occlusion both during and after angioplasty (PTCA). Intracoronary or sys-
temic urokinase (UK) does not reduce the rate of untoward clinical events in
patients with ischemic syndromes but local UK may potentially be effective.
This double-blind, randomized, prospective study evaluated periprocedursd
and long-term clinical events of 54 patients with acute ischemic syndromes
who underwent urgent and emergent PTCA and local delivev of either saline
(control) or UK by a hydrogel coated balloon during PTCA. Fibrinopeptide A
(FPA), a marker of thrombin activity was sampled from the coronary sinus
before and after PTCA and correlated to clinical events. Adverse procedural
events were defined as a composite of reocclusion of the artery, emergent
bypass surgery or the presence of thrombus after two balloon inflations. The
6 month follow-up was a composite of death, infarction or restenosis. Re-
sults: Minimal Iuminal diameters before and after PTCA in both groups were
similar. There was no difference in the periprocedural results of the patienta
randomized to saline or UK. Patients randomized to UK had a statistically
significant increase in events over six months (48’Yovs. 24%, p = 0.04). UK
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delivery increased FPA levels (12.5 +=3.5 vs. 2.8 & 0.8 rig/ml, p = 0.019)
compared with patients without events. Patients with events had significantly
increased FPA levels prior to (18.9 + 4.1 vs. 6.1 + 1.1 n~ml, p = 0.001) and
after PTCA (11.8+3.8 vs. 5.1 + 1.9 rig/ml, p =0.03). SUrnrnary:PTCA in the
setting of increased FPA levels was associated with an increased event rate
at 8 month follow-up. Intramural delivery of urokinase increased the clinical
event rate over a 8 month follow-up. The results support the hypothesis
that increased thrombin activity and/or thrombin formation plays a role in
restenosis.
D802 Stents: Difficult Lesions
Wednesday,March 19, 1997, 4:00 p.m.–5:OOp.m.
AnaheimConventionCenter,Arena
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El8021 CPKRiseAfterSaphenousVeinGraftIntervention:AngiogrsphicPredictorssndClinicalOutcomes
S.R. Bailey, D. Snead, R.S. Kiesz, M. Savage, D.L. Fischman, J. Douglas,
C. Pepine, J. Werner, R. Rake, S. Goldberg. The University of TexasHealth
SCMIC.S Cefrter@San AntoniO,San Antonio, Texas,USA
Saphenous vein graft interventions (SVGI) are associated with a significant
risk of distal embolization and CPK elevation. CPK elevations in native
vesaels are associated with increased clinical events after interventions. We
report the substudy analyaia from the Saphenous Vein De novo (SAVED)trial
evaluating CPK elevations in the 223 lesions from 220 patients randomized
to balloon angioplasty (6A) or Palmaz Schatz (PS) stent.
We evaluated the correlates of CPK elevation stratified as <2x, 2 – 5x
and >5x normal. No difference in CPK rise was noted between PS or BA
groups. CPK rise correlated with larger vessel size (3.16+ 0.55 mm vs 3.91
+ 0.72 mm) P <0.001, and lesions longer than 15 mm (P c 0.01) but not
angiographic thrombus or graft age. Balloon to artery ratios were smaller
and maximal inflation pressures lowerin patients with CPK elevation. CPK
elevation predicted longer hospital stays (5.1 +5.4 days vs 12.2 +8.2 days,
p < 0.01) and an increased riakof death (1/177< 2x, 1/17 >2 <5x, 2/6 >5x,
P < 0.001). We conclude that 1) CPK elevation during SVGI occurred more
frequently in larger vessels and longer lesions consistent with greater plaque
burden. 2) CPK elevation =- 5 x normal was associated with more frequent
early Ml and death. 3) CPK elevation was not relatedto high pressure inflation
over sized balloons or grafl age.
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El8022 ContemporaryPercutaneousTreatmentofUnprotectedLeftMeinCoronaryStenoses- An
Updatefromthe ULTIMARegistry
S,G. Ellis, H. Tamai, M. Nobuyoshi, A. Colomtm, D.R. Holmes, K. Kosuga,
C.L. Grines for the ULTIMA Regist~. Cleveland C/inic Foundation,
Cleveland, OH, USA
Recent single site experience with debulking and stenting of unprotected left
main stenoses (ULMS) has led to a re-evaluation of the role of percutaneous
treatment (perc m) in theee patients (pts). To amalgamate experience with
perc rx of ULMS, we formed a Registry 3/96 and have reported preliminary
results (n = 38). The purpose of this report is to update our experience (n =
100), focusing on pt subgroups,
Subgroup In-hospitalDesth 6 Month(%) Restenosis Death cOmD
(%) (%) (%)
3fableangina(n=46) &5 29.7 19.6 19.6
Unetableanghra[n =41) 14.6 48.1 39.0 48.7
CABGcandidate*(n= 66) 4.6 28.6 16,9 19.0
RsfueedforCABG*(n= 21) 23.8 85.7 65.0 70.0
Stent*(n=42) 0,0 33.3 t9,0 32.6
DCA*(n= 24) 6,3 21.7 12,5 12.5
Othsrtraatment*(n= 21) 28.8 70.0 47,6 47.9
*excludes pta withacute Ml, Comp=cardiac death, Ml, or CABG
These preliminary data suggest: 1) when perc m of ULMS is necessary,
stent or DCAia preferred; 2) although stent/DCAforstable angina and CABG
candidate gives fair results, except for a 3-5% incidence of sudden death
within 6 mea, resulte with other groups appear unfavorable: 3) Perc rx of
ULMS with present technoiogyshould be performed cautiously,perhaps with
angiogrephic follow-up at 2-3 mos to identify pts with early (and petiaps
life-threatening) restenosie.
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ChronicCoronaryArteryOcclusion:Reductionof
Restenosis-andReocclusion-RatesbvStent
Treatment
D.G. Mathey, A. Seidensticker, T. Rau, K.-P. Kunze, J. Schofer. Cerrferfor
Cardiology Hamburg-Othmarschen, Germany
Recanalization of chronic coronary artery occlusions by balloon angioplasty
is associated with a non-occlueive restenosis rate of about 30% and a
raocclusion rate of about 20%. It was the “objective of this study to eesese
restenosis- and reocclusion-rates after stent placement and to determine
factors predicting restenosie and reocclusion.
In 143 patients chronic coronary occlusions were recanalized and sub-
sequently treated by stenting. Stentimplantation was performed with high-
-pressure dilatation (14-18 atm) using mainly Palmaz-Schatz and AVE-
Microstents. Medical treatment was with ASA (100 mg/d) in combination with
ticlopidine for 4-12 weeks. Control angiography was performed in 120/143
patients 10 to 40 weeks (mean 19 weeks) after successful recenalization.
Repeat angiography revealed no restenosis in 67 vessels (72Yo).Restenosis
?50?4was found in 34 vessels (26%) including reocclusion in 7 vessels (6%).
Vessels with restenosis had a significantly smaller minimal Iuminal diameter
(MLD) after stent-implantation as compared to vessels without reatenosia (p
= 0.03); vessels which were reoccluded at follow-up had a smaller MLD anda
smaller reference diameter as compared to vessels without reocclusion (p <
0.03). Symptoms of the patients were markedly improved. At follow-up nearly
60% of patients were asymptomatic whereas prior to intervention more than
70% of patients were in CCS-Class 2 or higher.
Conclusions: 1.Stent treatment of chronic coronary artery occlusion
cleartyreducesthe restenosisand reocclusion rate. 2. Symptoms are markedly
reduced or abolished in most of the patients. 3. MLD after the procedure and
the diameter of the reference segment were significant predictors of resteno-
siehocclusion after stent treatment for chronic occlusion.
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1802-41stentin~insma,,vesse,s:ARe*va,uationusing~he
GRIIIntracoronaryStentine MulticenterRegistry
Study
L.S. Dean, J.P. Zidar, W.D. Voorhees, DR. Holmes, Jr.,
C.D. O’Shaughnessy, P.B. Moore, E.W. Rogers, R.R. Heuser, G.S. Roubin,
M.B. Leon for the Cook GRII investigator. University Of A/abaf7r8 at
Birmingham, Birmingham, AL, USA
Previous experiences using corona~ stents in small vessels have produced
mixed results. To determine the safety and efficacy of the newly designed
GRII atent in small (<3.0 mm) vessels, a multicenter registry waeformed and
thusfar, 21 centers have enrolled 128 patients. C/inica/demographics: 62.5%
males, mean age 62.4 + 11.6 years, 32.6% prior Ml, 80% de novo lesions,
84.8% multivessel disease, and.mean ejection fraction 58.2+ 11.3%. Lesion
characteristics: mean vessel diameter 2.8 + 0.4 mm, lesion length 12.5 +
6.2 mm, B2 and C leaions 63.6%, diffuse diaease 35.29’o,and moderate
or severe proximal tortuosity 327.. Procedural details: stent sizes were 2.5
mm in 36.1% and 3.0 mm in 55.4%. Post-stent high pressure (=-14 atm)
adjunct PTCA was routinely applied without frequent ultrasound guidance
and the routine anticoagulation regimen was aspirin plus ticlopidine. Resu/fs:
Angiographic success was achieved in 99.2% of patients. 30-day clinical
outcomes include death in 0.6%, CABG in 0.8Y0,no Q-wave Ml’s, subacute
stent thrombosis in 3.1%, and repeat PTCA in 2.3%. In conclusion:The new
GRII stent (1) can be used to treat complex lesions in tortuous small veesels
with vety high success rates and (2) major adverse events (death, Ml, CABG,
or repeat PTCA) are infrequent in the firat thirty days. Thus, if late follow-
up results are similarly favorable, future clinical trials would be indicated to
assesethe relative value of the GRII stent compared with conventional PTCA
in small vessels.
